Intracystic treatments for craniopharyngioma

Neurosurg Focus. 2010 Apr;28(4):E13. doi: 10.3171/2010.1.FOCUS09315.


Craniopharyngioma is a benign tumor histopathologically and in theory should be curable by radical resection. In practice, this tumor behaves like a chronic disease, with many issues related to the effect of the tumor itself and the various treatments on the adjacent structures, such as the pituitary stalk and gland, hypothalamus, visual apparatus, and suprasellar arteries. A multimodality approach to the management of these tumors may produce the optimal outcome, balancing disease control and quality of life. In this paper, the role of intracystic therapies is reviewed, with the major focus on intracystic bleomycin and interferon-alpha.

Publication types

  • Review

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / therapeutic use*
  • Bleomycin / administration & dosage
  • Bleomycin / therapeutic use*
  • Combined Modality Therapy
  • Craniopharyngioma / diagnostic imaging
  • Craniopharyngioma / drug therapy*
  • Craniopharyngioma / radiotherapy
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Injections, Intralesional
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Pituitary Neoplasms / diagnostic imaging
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / radiotherapy
  • Radionuclide Imaging
  • Radiotherapy, Conformal
  • Treatment Outcome


  • Antibiotics, Antineoplastic
  • Immunologic Factors
  • Interferon-alpha
  • Bleomycin